Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07116967 · ClinicalTrials.gov registry record · Phase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
A Phase 3 study of Plaque Psoriasis, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 3,040
- Enrollment target
- 20
- Study locations
NCT07116967 is a Phase 3 study of Plaque Psoriasis that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 3,040 participants, above the 348-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (774% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT07116967, a Phase 3 study of Plaque Psoriasis, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 3,040 participants
- Enrollment target
- 20
- Study locations
Study Summary
A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis
Conditions Studied
Interventions
- DRUG Ustekinumab
- DRUG Deucravacitinib
Study Locations (20)
California
- California Dermatology & Clinical Research Institute - Encinitas
- T. Joseph Raoof MD Inc - Encino
- Center For Dermatology Clinical Research, Inc. - Fremont
- Marvel Clinical Research - Huntington Beach
- Dermatology Research Associates - Howard Sofen, MD - Los Angeles
- Local Institution - 0192 - Los Angeles
- Northridge Clinical Trials - Elite Clinical Network - Northridge
- Cura Clinical Research - Palmdale - Palmdale
- Pasadena Clinical Trials - Pasadena
- Empire Clinical Research - Pomona - Pomona
Arizona
- Medical Dermatology Specialists - Phoenix - Phoenix
- Saguaro Dermatology - Phoenix - Phoenix
- Omni Dermatology - Phoenix
- Alliance Dermatology - Phoenix
- Local Institution - 0322 - Scottsdale
- Local Institution - 0188 - Scottsdale
- Scottsdale Clinical Trials - Scottsdale
- Omni Dermatology - Tempe
Alabama
- Local Institution - 0088 - Birmingham
Arkansas
- Clinical Trials Institute of Northwest Arkansas - Fayetteville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,040 participants |
| Start Date | 2025-09-22 |
| Est. Completion | 2031-01-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07116967
The ClinicalTrials.gov registry entry for NCT07116967 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 3,040 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 348-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (774% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Ustekinumab is the first listed.
NCT07116967 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT07116967 about?
NCT07116967 is a clinical study titled "Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)". A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis
What is the current status of trial NCT07116967?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 3,040 participants. The study started on 2025-09-22. Estimated completion is 2031-01-16.
What conditions does trial NCT07116967 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT07116967?
The interventions under investigation include: Ustekinumab (DRUG), Deucravacitinib (DRUG).
Who is sponsoring clinical trial NCT07116967?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07116967 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
ACTIVE NOT RECRUITING · Phase 3
-
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
ACTIVE NOT RECRUITING · Phase 3
-
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.